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Background: Even though malaria is a completely preventable and treatable disease, it remains a threat to human life
and a burden to the global economy due to the emergence of multiple-drug resistant malaria parasites. According to
the World Malaria Report 2013, in 2012 there were an estimated 207 million malaria cases and 627,000 deaths. Thus,
the discovery and development of new, effective anti-malarial drugs are required. To achieve this goal, the Department
of Chemistry at the University of the Free State has synthesized a number of novel amino-alkylated chalcones and
analogues, which showed in vitro anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant
Plasmodium falciparum strains. The lead compound (NP046) was selected for a comprehensive pharmacokinetic (PK)
and in vivo efficacy evaluation in a mouse model.
Methods: In vivo efficacy: Water solutions of NP046 were administered orally at 50 and 10 mg/kg using oral gavage
and IV at 5 and 1 mg/kg via the dorsal penile vein to Plasmodium berghei (ANKA strain) infected male C57BL/6 mice
(n = 5), once a day for four days. Blood samples were collected via tail bleeding in tubes containing phosphate buffer
saline (PBS) on day five to determine the % parasitaemia by flow cytometry.
In vivo PK: NP046 solutions in water were administered orally (50 and 10 mg/kg) and IV (5 mg/kg) to male C57BL/6
mice (n = 5). Blood samples were collected via tail bleeding into heparinized tubes and analysed using a validated
LC-MS/MS assay. Data obtained from the concentration-time profile was evaluated using Summit PK software to
determine the PK parameters of NP046.
Results: NP046 inhibited parasite growth for the oral and IV groups. Better parasite growth inhibition was observed for
the IV group. The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg
dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.
Conclusion: Even though the oral bioavailability of NP046 is low, its percentage parasite growth inhibition is promising,
but in order to improve the oral bioavailability, structure-activity-relationship (SAR) optimization studies are currently
being conducted.
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Although malaria is completely preventable and treatable
[1] it remains a threat to human life and a burden to the
global economy due to the emergence of multi-drug
resistant malaria parasites.
Artemisinin-based combination therapy (ACT) is
recommended as first-line treatment for uncomplicated
Plasmodium falciparum malaria [2,3] and has significantly
reduced the malaria burden in most endemic countries,
but the emergence of artemisinin-resistant malaria
parasites in Cambodia, Myanmar, Thailand and Vietnam
[1-3] underscores the importance and urgency to push the
discovery and development of new effective anti-malarial
drugs to its highest level.
Thus to achieve this goal, the Department of Chemistry
at the University of the Free State has synthesized a num-
ber of novel amino-alkylated chalcones and analogues by
means of the Mannich reaction. The compounds were
evaluated for their in vitro anti-malarial activity against
chloroquine-sensitive (D10) and chloroquine-resistant (K1)
P. falciparum strains, and cytotoxicity against Chinese
Hamster Ovarian (CHO) cells by MTTassays [4].
In this study the in vivo efficacy and PK evaluation of




Animal experiments were performed at the animal unit
of the PK laboratory of the University of Cape Town,
division of clinical pharmacology following the grant of
ethical approval from the Animal Research Ethics
Committee of the Faculty of Health Sciences of the
University of Cape Town (project no. 011/022).
Reagents and chemicals
NP046 (C21H26FNO, MW= 327.4) was synthesized and
its HPLC purity was determined to be > 99% (for details
of the synthesis see Additional file 1). All chemicals and
reagents used in this study were of analytical grade or
ACS (American Chemical Society) grade. Ammonium
formate (97% pure), sodium acetate (purity > 99%),
chloroquine phosphate and PEG400 were purchased from
Sigma-Aldrich Gmbh (Steinheim, Germany), formic acid
(98 – 100%), tert-butylmethyl ether (purity > 99%) and
ethanol (GC > 99.9%) were purchased from Merck KGaA
(Darmstadt, Germany), acetonitrile and methanol (all ofFigure 1 NP046.high-purity grade) were purchased from Honeywell,
Burdick & Jackson (Muskegon, MI 49442, USA). Water
used to prepare solutions was purified by a Millipore
Elix 10 reverse osmosis and Milli-Q® (Millipore, USA)
Gradient A 10 polishing system.
Environmental conditions for the animals
Male C57BL/6 mice 12 to 16 weeks old, weighing 20 to
25 g were obtained from the University of Cape Town`s
animal unit. They were kept in cages (a maximum of 5
mice per cage) in a temperature-controlled room with a
12 hours day/night light cycle. Ample dried food and
water were supplied, and their sanitation was monitored
daily. The animals were acclimatized to the test environ-
ment for 3 to 4 days before the experiment started.
In vivo efficacy evaluation
Plasmodium berghei transfected with green fluorescence
protein (strain ANKA), a chloroquine-sensitive strain,
was stored in liquid nitrogen. Parasites were thawed and
administered intraperitoneally (IP) to infect two donor
mice a week before the experiment commenced. Then the
parasite-infected red blood cells (RBCs) were collected into
heparinized tubes by tail bleeding and the parasitaemia was
determined using flow cytometry (≥15%). Finally, each of
the test animals received 200 μl of the P. berghei-infected
RBCs (1×107 per 200 μl PBS) IP to infect them with the
parasite. There were three animals per dose group, and each
of them received 200 μl of NP046 in water orally and intra-
venously (volume adjusted relative to the weight of mouse)
at their respective dose concentration as shown below:
 Group A: 50 mg/kg (oral) ≡ 6.25 mg/ml
 Group B: 10 mg/kg (oral) ≡ 1.25 mg/ml
 Group C: 5 mg/kg (IV) ≡ 0.625 mg/ml
 Group D: 1 mg/kg (IV) ≡ 0.125 mg/ml
 Group E: the negative control group received the
drug vehicle alone (placebo)
 Group F: the positive control group received
10 mg/kg CQ (oral) = 1.25 mg/ml (free base)
The test compound was administered to the animals
once a day for four days. The first dose was administered
two hours after infection on day one, followed by the
second, third and fourth dose at intervals of 24 hours.
Blood samples were collected via tail bleeding in tubes con-
taining PBS on day 5, and % parasitaemia was determined
with FACSCalibur™ using the software CellQuestPro [5].
Finally, the percentage parasite growth inhibition was
calculated using the following equation [6]:
% growth inhibition ¼ Parasitemiaof negative−Parasitemiaof test sample
Parasitemiaof negative
 100
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The in vivo PK properties of NP046 were evaluated
following oral (50 and 10 mg/kg) and IV (5 mg/kg)
administration of the compound in water to male
C57BL/6 mice (n = 5). Blood samples were collected
via tail bleeding in heparinized tubes at predetermined
sampling times on ice, and were stored at −80°C until ana-
lysis. Despite the critical problem of obtaining numerous
blood samples from a mouse without compromising the
health/safety of the animal, blood samples at all the
sampling times, i.e. 0.17, 0.5, 1, 3, 5 and 7 hours for the IV
dose groups, and 0.5, 1, 3, 5 and 7 hours for the oral dose
groups were collected from each mouse. The extraction
volume during sample analysis was targeted at the lowest
possible volume (20 μl) thereby minimizing the total
volume of blood harvested from the animal.
Blood samples collected from mice following the
administration of NP046 together with the calibration
standards (STDs) and quality controls (QCs) of NP046
were analyzed using a validated LC-MS/MS assay
(for details of the LC-MS/MS assay see Additional file 2).
Concentration vs time profiles were constructed and using
Summit PK software the data were processed to obtain
the PK properties of NP046.
Results and discussion
In vivo efficacy evaluation
The mean percentage parasitaemia (± S.E.M) and
percentage of parasite growth inhibition data of NP046 in
P. berghei-infected mice assessed on day five post-infection
is presented in Table 1, and the summary chart of the
percentage of parasite growth inhibition is presented
in Figure 2. The 50 and 10 mg/kg NP046 oral dose
groups resulted in percentage of parasite growth inhibition
of 47.3% and 24.6%, respectively, while the 5 and 1 mg/kg
NP046 IV dose groups resulted in 87.4% and 57.6% growth
inhibition, respectively, on day five post-infection relative
to the negative control (placebo) group. The IV dose group
showed a higher percentage of parasite growth inhibition
relative to the oral dose group, which correlates well withTable 1 Mean percentage of parasitaemia (± S.E.M) and
percentage of parasite growth inhibition data of NP046
in P. berghei-infected male C57BL/6 mice, assessed on
day five post-infection
Treatment % parasitaemia % growth inhibition
50 mg/kg NP046 oral 16.7 ± 3.34 47.3
10 mg/kg NP046 oral 24.3 ± 0.80 24.6
5 mg/kg NP046 IV 4.05 ± 0.12 87.4
1 mg/kg NP046 IV 10.2 ± 1.75 57.6
Positive control 0.01 ± 0.0 100
Negative control 32.2 ± 0.50 0the poor oral absorption of NP046 as presented in the next
section.
Compounds that reduce parasitaemia by 30% or more
are considered active and are further evaluated in second-
ary screens [7]. Thus, NP046 which exhibited a 47.3%
reduction in parasitaemia at a 50 mg/kg oral dose relative
to CQ can be considered as an active compound and
proceed for further secondary screens.
In vivo PK evaluation
Blood samples collected from mice after the administra-
tion of NP046, together with the calibration standards
(STDs) and quality controls (QCs), were analysed using a
fully validated LC-MS/MS assay. NP046 concentrations
were detectable for up to seven hours after oral and IV
dosing. Concentration vs time profiles (Figures 3 and 4)
were constructed and the data processed with Summit PK
software (non-compartmental analysis) to obtain the PK
parameters as presented in Table 2. The LC-MS/MS
method performed very well; NP046 concentrations in the
mice were detectable for up to seven hours after both
50 and 10 mg/kg oral dosing, with mean concentra-
tions of 0.05 and 0.02 μM, respectively. In contrast to
oral dosing, the 5 mg/kg IV dose resulted in a mean
blood NP046 concentration at seven hours after dosing
of 0.14 μM.
The oral dose regimens of NP046 showed dose-
dependent PK relationships, i.e. increasing the oral dose
from 10 mg/kg to 50 mg/kg increased the AUC from 30
to 80 min.μmol/L. The mean elimination half-life of
NP046 following oral administration was 4.4 hours and
3.1 hours for the 50 mg/kg and 10 mg/kg doses, respect-
ively, while for the IV route it was 3.2 hours, indicating a
moderate elimination half-life. The compound has a very
high volume of distribution (16.9 L/kg), indicating high
distribution of the drug in tissues. The estimated oral
bioavailability of NP046 at 50 mg/kg and 10 mg/kg
were very low at 3.2% and 6.0%, respectively.
The oral bioavailability of NP046 was low. Low oral bio-
availability could be the result of the following reasons [8]:
 first-pass metabolism at the intestinal wall or portal
circulation to the liver, both common sites of
first-pass metabolism;
 poor water solubility of drug which results in slow
absorption, and thus, low bioavailability;
 membrane permeability; and
 chemical interactions, such as hydrolysis by the
gastric acid or enzyme, complex formation,
conjugation in the intestinal wall, etc., which affect
absorption could also affect bioavailability.
Therefore, investigating some of the reasons for low bio-
availability in the early stage of the drug development
Figure 2 % parasite growth inhibition chart for NP046 in P. berghei-infected mice (n = 5) on day five post-infection.
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stability, solubility, etc., is helpful in enhancing the drug
development process. Thus, in this study the following
investigations on some of the probable causes for low
bioavailability were performed:





Plasma protein binding assessment
PPB (plasma protein binding), the extent to which a drug
binds to protein in plasma, can affect the PK-PD propertiesFigure 3 Mean blood concentration vs time profiles of NP046 followi
to male C57BL/6 mice (n = 5).of a drug. Thus, determining the PPB property of a drug in
the early stage of drug development process is crucial and a
prerequisite for lead prioritization [9]. Initially the PPB assay
was performed using an ultrafiltration method [see
Additional file 3], which depends on centrifugal force to
move the unbound analyte of interest through a size-
selective membrane. Ultrafiltration is recommended for the
determination of PPB property if the non-specific binding
(NSB) of the test drug to the micro-partition device is less
than 5%. If NSB > 5%, an alternative technique such as equi-
librium dialysis or ultracentrifugation should be used [9].
In this study, since the NSB > 5%, ultracentrifugation was
used to assess the PPB property of NP046 [for the method-
ology see Additional file 3]. NP046 showed a moderate PPB
property, i.e. 28% at 1000 ng/ml and 20.3% at 10 ng/ml.ng oral administration of 50 and 10 mg/kg NP046, respectively,
Figure 4 Mean blood concentration vs time profiles of NP046 following IV administration of 5 mg/kg NP046 to male C57BL/6 mice (n = 5).
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Kinetic solubility is the measurement of the solubility of
a pre-dissolved compound (typically in DMSO, a strong
organic solvent) in an aqueous buffer [10]. Solubility,
one of the most important properties in a drug discovery
process, is a determinant factor in intestinal absorption
and oral bioavailability. In other words, for a drug to be
absorbed and became available in the systemic circulation
and to act on the target cell, irrespective of its formulation
or route of administration, it should go into solution, i.e. it
should be able to dissolve and diffuse through the intes-
tinal membrane [10]. The kinetic solubility of NP046 was
determined using an HPLC-UV method at pH 2.0 and 7.4
[for the methodology see Additional file 4]. The concen-
tration of the test compound (x) in PBS samples was
calculated from the peak area (y) in its UV chromatogram
by extrapolation from the three-point calibration line,
using the equation y = ax + b; where a = slope and
b = intercept. The results are presented in Table 3.
The pH of the stomach is approximately 1.4 to 2.0, and
that of the intestine where drug absorption takes place is
approximately pH 6.8 to 8.0 [11]. NP046 is highly solubleTable 2 PK parameters of NP046
PK parameter Oral IV
Nominal Dose (mg/kg) 50 10 5
Apparent t1/2 (h) 4.4 ± 0.60 3.1 ± 0.46 3.2 ± 0.35
Blood CLtotal (mL/min/kg) — — 62.2 ± 3.0
Vd (L/Kg) — — 16.9 ± 1.3
Cmax (μM) 0.47 ± 0.10 0.13 ± 0.06 —
Tmax (min) 30 48 —
AUC0 - ∞ (min. μmol/L) 80 ± 8.8 30 ± 14.7 248 ± 12.6
Bioavailability (%) 3.2 ± 0.47 6.0 ± 2.9 N/A
Results are mean of n = 5 ± S.E.M.at pH 2.0 indicating that it can dissolve in the stomach
and pass into the intestine (pH 6.8 – 8) where it starts to
precipitate as its solubility at pH 7.4 is very low. Thus its
ability to diffuse through the intestinal membrane and get
absorbed is limited resulting in a very low oral bioavail-
ability as shown in the PK evaluation experiment.
Metabolic stability
Metabolism is an enzymatic process in which a drug is
chemically modified into polar metabolites that can be
more readily excreted from the body. Metabolism occurs
mainly in the liver, and the intestine [10]. The metabolic
stability of NP046 was determined in human and mouse
liver microsomes using a multiple-time-point method at
0, 5, 10, 30, and 60 minutes [for the methodology see
Additional file 5]. The in vitro intrinsic clearance values
of NP046 in human and mouse liver microsomes were
118.7 μl/min/mg and 656.8 μl/min/mg, respectively,
which are considered high and require a metabolism SAR
optimization of NP046 to improve its metabolic stability.
Permeability
Permeability is the speed/velocity and extent to which
a drug passes through a biological membrane obstacle
in a living system, such as the gastrointestinal (GI)
epithelial cells, the blood capillary wall, the target cell
membrane [10]. The Caco-2 cell line (a continuous line ofTable 3 Kinetic solubility of NP046 and controls
Compounds Solubility (μM)
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oma cells), the most widely used and recognized as a
model of the intestinal barrier [11] was used to determine
the in vitro permeability of NP046 [for the methodology
see Additional file 6].
The transport of each drug from the apical side to the
basolateral side was done using a transport buffer that con-
sisted of Hank’s Balanced Salt Solution (HBSS) + 10 mM
HEPES + 0.35 g/ml NaHCO3, pH 7.4 (1:100 1 M HEPES in
HBSS). The drug transport assay was performed by deter-
mining the concentrations of the test compound from the
basolateral chamber, using an LC-MS/MS assay. But no
quantifiable amount of the test compound was found in the
solution obtained from the basolateral chamber. Therefore,
the experiment was repeated and the same result was
obtained. This could be due to the following reasons:
 the compound was bound to the membrane of the
device (6.5 mm Transwell with 0.4 μm pore
polycarbonate membrane insert) as it happened
during plasma protein binding assessment using the
ultrafiltration method, i.e., high NSB to the
membrane of the device; or
 a solubility problem, in that the test compound
showed very low solubility at pH 7.4. Therefore, as
the pH of the transporter buffer was 7.4, the test
compound might have formed a precipitate resulting
in poor permeability.
Lipophilicity
Lipophilicity is a compound’s tendency to partition into
a non-polar lipid matrix versus an aqueous matrix [10].
It is an important property of a drug which has a significant
influence on the drug ADME/tox properties as well as its
biological activity. In this paper, the distribution coefficients
(Log DpHx) of NP046 and controls (ouabain, hydrocortisone
and verapamil) were determined using a scaled-down
shake-flask method that had been adapted for a 96-well
plate in order to enable a high throughput.
Stock solutions of NP046 and controls in DMSO
(10 mM) were prepared and an aliquot of each phase
(octanol/PBS) was analysed by an HPLC-Diode array de-
tector (DAD) method. Chromatographic separation was
achieved on a Phenomenex® Kinetex C18 (50 × 2.1 mm i.d.
2.6 μm) column with a gradient elution, using mobile phase
(A) 5 mM ammonium format-acetonitrile (95:5, v/v) and
(B) 5 mM ammonium format-acetonitrile (5:95, v/v). The
Log D values were calculated using the analyte peak areas
obtained from each phase (Octanol/PBS) according to the
following equation [12]:LogD7:4 ¼ Log10
peak area of octanol phase=octanol ph
peak area of buffer phase=buffer phas

The Log D7.4 for NP046 was found to be 2.6, which is
in the ideal range (Log D7.4 1 to 3), and is expected to
have good intestinal absorption but minimum metabolism.
However, its oral bioavailability was low which could have
resulted from intestinal metabolism leading to first-pass
extraction. The small intestine, which is estimated to have
about 1% CYP3A of the average hepatic content, has the
ability to metabolise drugs resulting in first-pass extraction
more than the hepatic metabolism for some drugs leading
to limited oral bioavailability [13].
Conclusion
Even though the oral bioavailability of NP046 is very
low, its parasite growth inhibition was moderate at a
50 mg/kg oral dose and high at a 5 mg/kg IV dose, i.e.
47.3% and 87.4%, respectively. The lower parasite
growth inhibition with oral dosing relative to the IV
dosing correlates well with poor oral bioavailability. A
SAR optimization process has been triggered by these
results and a next generation of analogues has been
synthesized by the Department of Chemistry of the
University of the Free State, and is currently being evaluated
for their bioavailability and efficacy properties.
Additional files
Additional file 1: The synthesis of nitrogen containing chalcones
and analogues. The data provided describes the method used to
synthesize the nitrogen containing chalcones and analogues, and the
resulting NMR and IR data.
Additional file 2: LC-MS/MS assay for the analysis of NP046. The
data provided describes the detection and chromatography, sample
preparation and some validation results from the LC-MS/MS assay used
to analyse NP046 PK-samples.
Additional file 3: Plasma protein binding (PPB) assay procedure.
The data provided describes the procedure used for the determination of
nonspecific binding of the test drug to the micro-partitioning device followed
by the PPB-assay using ultrafiltration and ultracentrifugation methods.
Additional file 4: Summary of the assay method for the
determination of kinetic solubility. The data provided describes the
assay procedure used for the determination of the kinetic solubility of
the test drug.
Additional file 5: Summary of the assay method for the determination
of microsomal stability. The data provided describes the assay procedure
used for the determination of the microsomal stability of the test drug in
human and mouse microsomes.
Additional file 6: Caco-2 permeability assay protocol. The data
provided describes the assay procedure used for the determination of the
permeability of the test drug through a biological membrane.
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